bioAffinity Technologies vs OneMedNet
bioAffinity Technologies reported revenue of $6 million in fiscal 2025, 4.4 times OneMedNet's $1 million in fiscal 2025. bioAffinity Technologies' revenue fell 34.2% in its latest year, and OneMedNet's grew 111.3%. bioAffinity Technologies had an operating margin of -171.6%, against -711.3% at OneMedNet. Free cash flow was −$9 million at bioAffinity Technologies and −$8 million at OneMedNet.
Side by side
| bioAffinity Technologies | OneMedNet | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $6M | $1M |
| Revenue growth | −34.2% | 111.3% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | −37.0% |
| Operating margin | −171.6% | −711.3% |
| Net margin | −242.0% | −206.1% |
| Free cash flow | −$9M | −$8M |
| Free cash flow margin | −152.4% | −553.0% |
| Return on capital | −400.1% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 325.8% | 58.7% |
| Last close | $1.85 | $4.51 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $1.0 million, sold $1.2 million | — |
| Piotroski F-score | 3 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
bioAffinity TechnologiesOneMedNet
Operating margin
Percent of revenue
bioAffinity TechnologiesOneMedNet
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
bioAffinity TechnologiesOneMedNet
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the bioAffinity Technologies and OneMedNet pages.